Clinical DevelopmentThe strategic decision to focus resources on clinical development and reduce commercial spending is a sound one.
Financial PerformanceBioXcel Therapeutics reported top-line revenue of $1.1M, beating the forecast of $0.8M, driven by sales of its sole approved product IGALMI™.
Market OpportunityBTAI's most recent market research suggests that the schizophrenia/bipolar disorder at-home market opportunity may be larger than the 23 million episodes it initially had estimated.